BIAF surges into Tuesday’s session as lung cancer diagnostic momentum builds

NEW YORK, March 24, 2026 — BioAffinity Technologies (NASDAQ: BIAF) is extending one of the most aggressive small-cap premarket runs of the session, adding approximately 20% to 40% in early Tuesday trading after surging 85% on Monday to break above its 200-day moving average for the first time since April 2025. The move places BIAF up more than 160% over the past week and more than 300% year-to-date, as the market prices in accelerating commercial momentum around its flagship noninvasive lung cancer diagnostic, CyPath Lung.

BIAF: What is driving the premarket surge in BioAffinity Technologies stock

The catalyst behind BIAF’s extended run is a combination of strengthening clinical data, expanding commercial traction, and a freshly initiated large-scale study that signals the company is transitioning from early-stage validation into broader institutional deployment. Last week, BioAffinity published a clinical case study demonstrating CyPath Lung’s utility in physician decision-making — a 71-year-old former smoker with multiple lung nodules was assessed using the test, which indicated low malignancy risk and allowed the patient’s team to defer an invasive procedure. The case study resonated with retail traders tracking the stock, contributing to an initial 40% single-session move last Tuesday.

That momentum accelerated into Friday’s session following the company’s full-year 2025 results, which showed record CyPath Lung revenue and unit sales. Management reported an 87% year-over-year increase in CyPath Lung test revenue, with volumes rising 99% — confirming that clinical adoption is scaling at a rate that exceeds broader diagnostic market benchmarks. Total company revenue declined to $6.2 million from $9.4 million as BioAffinity exited non-core pathology services to concentrate resources on its core diagnostic platform, a strategic pivot that the market appears to be rewarding.

CyPath Lung clinical data: accuracy metrics and the 2,000-patient trial

CyPath Lung is a noninvasive flow cytometry test that analyses cells in a patient’s sputum sample using artificial intelligence to assess lung cancer risk. Published data shows the test has achieved 92% sensitivity, 87% specificity, and 88% accuracy in nodules smaller than 20 millimetres — performance metrics that position it as a meaningful adjunct to low-dose computed tomography (LDCT) screening in high-risk populations.

On March 13, 2026, BioAffinity initiated a 2,000-patient longitudinal clinical study (NCT07168993) across up to 20 sites including Veterans Affairs centres and major military hospitals. The study targets patients with lung nodules between 6mm and 30mm — a high-risk population that frequently faces difficult triage decisions between watchful waiting and invasive biopsy. Enrolment is expected to continue for approximately 18 months with follow-up extending to 24 months. The investigational assay in this trial is designated FlowPath Lung.

BioAffinity also secured a validation study with Brooke Army Medical Center to test CyPath Lung on sputum obtained via tracheal and bronchial suctioning, with results anticipated by mid-2026. The company ended 2025 with $6.5 million in cash following $16.9 million in financings completed during the year — a capital position that analysts will scrutinise given the burn rate associated with its clinical development agenda.

Analyst reaction and market sentiment around BIAF’s premarket run

Institutional analyst coverage of BIAF remains thin given its micro-cap status — the company’s market capitalisation sits at approximately $12.28 million — but retail sentiment on platforms such as Stocktwits has remained in bullish territory throughout the current rally, with message volumes described as “extremely high.” Multiple users have flagged the company’s international patents and advancing COPD and asthma diagnostics pipeline as potential additional valuation drivers.

The company also added three nationally recognised pulmonary and lung cancer specialists — David Ost, MD, MPH; Daniel Sterman, MD; and J. Scott Ferguson, MD — to its Medical and Scientific Advisory Board in February 2026, a credentialing move that has supported clinical adoption discussions. BioAffinity’s Precision Pathology Laboratory Services (PPLS) subsidiary also maintained its College of American Pathologists (CAP) accreditation following a rigorous on-site inspection.

What to watch at the open — key risks and levels for BIAF heading into Tuesday’s session

Several risk factors warrant attention as the session approaches. BIAF is a micro-cap stock with a market capitalisation of approximately $12.28 million and just 57 employees — a profile that implies thin liquidity and elevated susceptibility to sharp reversals as momentum traders rotate. The stock reached an all-time low of $0.69 in February 2026 and is now trading near $5, representing a move that carries significant mean-reversion risk in the absence of durable fundamental catalysts.

The upcoming Q4 2025 earnings report on March 30 will be the next definitive catalyst. Analysts expect an EPS loss of $2.70 on revenue of $1.41 million — numbers that, if met, would reinforce the company’s ongoing cash burn profile. Traders monitoring the stock’s premarket behaviour will be watching whether Tuesday’s session maintains the momentum from Monday’s 200-day moving average break, or whether the absence of fresh news triggers profit-taking. The stock’s beta coefficient of -2.94 makes conventional directional modelling particularly unreliable.

On the upside, continued enrolment news from the 2,000-patient longitudinal study, additional military hospital partnerships, or the Brooke Army Medical Center validation results could sustain institutional attention in the second half of 2026. The broader lung cancer diagnostics market — anchored by estimated annual U.S. lung cancer diagnoses exceeding 234,000 — represents a substantial addressable opportunity if CyPath Lung achieves broader clinical integration.

What the market is pricing in — and what remains unresolved

The market is currently pricing in a step-change in CyPath Lung’s commercial trajectory, driven by the 87% revenue growth figure, the 2,000-patient trial launch, and the multiple case studies demonstrating real-world physician adoption. What remains unresolved is whether the clinical validation momentum can translate into the scale of revenue needed to meaningfully reduce BIAF’s operating losses before its cash runway narrows. With $6.5 million in cash and a widening net loss of $14.9 million in FY2025, the pace of capital efficiency improvement will be a critical variable at the March 30 earnings call. For a stock that has moved from $0.69 to approximately $5 in just over a month, the bar for sustaining this valuation is set considerably higher than it was at the start of the year.

Investors seeking broader context on premarket trading dynamics or how healthcare sector catalysts typically behave around clinical data releases may find additional context in PreMarket Daily’s education series.